Literature DB >> 28994039

Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.

Julieann C Lee1, Melike Pekmezci1, Jonathan L Lavezo2, Hannes Vogel2, Laurence Katznelson3, Merav Fraenkel3, Griffith Harsh3, Mohanpal Dulai4, Arie Perry1, Tarik Tihan5.   

Abstract

Pit-1 immunostaining is not routinely used in the characterization of pituitary adenomas, and its utility in distinguishing adenomas dedicated towards the lactotroph, somatotroph, and thyrotroph lineage from null cell adenomas warrants further evaluation. Pituitary adenomas that were negative for expression of a basic panel of hormonal markers (ACTH, prolactin, and growth hormone) were further evaluated for TSH, SF-1, and Pit-1 expression using a tissue microarray. Among the 147 identified pituitary adenomas that were negative for ACTH, prolactin, growth hormone, and TSH, expression of SF-1 was present in 68 cases (46%). Of the remaining 72 cases with sufficient tissue for further analysis, four were Pit-1 positive (6% of the adenomas negative for ACTH, prolactin, growth hormone, TSH, and SF-1); the remaining 68 were potentially null cell adenomas. Two of the Pit-1-positive adenomas displayed a paranuclear CAM 5.2 staining pattern suggestive of a sparsely granulated somatotroph adenoma; however, only one case contained fibrous bodies within a majority of the adenoma cells. Our data suggests that Pit-1 can be utilized as a second tier immunostain in cases of clinically non-functioning adenomas that are immunonegative for ACTH, prolactin, growth hormone, TSH, and SF-1 in order to further segregate rare cases of Pit-1-positive adenomas from null cell adenomas. Pit-1 immunostaining can recognize rare cases of sparsely granulated somatotroph adenomas that appear immunonegative for growth hormone, as well as rare cases of other Pit-1-positive adenomas that are negative for Pit-1 lineage hormones. Overall, pituitary adenomas of the Pit-1 lineage that do not produce prolactin, growth hormone, or TSH are rare, with only four cases identified in the current study.

Entities:  

Keywords:  Clinically non-functioning pituitary adenoma; Null cell adenoma; Pit-1; Pituitary adenoma; SF-1; Silent adenoma; Sparsely granulated somatotroph adenoma; Transcription factors

Mesh:

Substances:

Year:  2017        PMID: 28994039     DOI: 10.1007/s12022-017-9503-6

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  12 in total

Review 1.  The pathogenesis of pituitary tumors.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

2.  The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.

Authors:  Hiroshi Nishioka; Naoko Inoshita; Ozgur Mete; Sylvia L Asa; Kyohei Hayashi; Akira Takeshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Yasuhiro Takeuchi; Shozo Yamada
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

Review 3.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics.

Authors:  James A Balogun; Eric Monsalves; Kyle Juraschka; Kashif Parvez; Walter Kucharczyk; Ozgur Mete; Fred Gentili; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

5.  A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours.

Authors:  Evelina Sjöstedt; Jens Bollerslev; Jan Mulder; Cecilia Lindskog; Fredrik Pontén; Olivera Casar-Borota
Journal:  Acta Neuropathol       Date:  2017-08-19       Impact factor: 17.088

6.  Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.

Authors:  Cheng-Chia Lee; Mary Lee Vance; M Beatriz Lopes; Zhiyuan Xu; Ching-Jen Chen; Jason Sheehan
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

7.  Pit-1 gene expression in human pituitary adenomas using the reverse transcription polymerase chain reaction method.

Authors:  S Yamada; M Takahashi; M Hara; A Hattori; T Sano; Y Ozawa; Y Shishiba; K Hirata; M Usui
Journal:  Clin Endocrinol (Oxf)       Date:  1996-09       Impact factor: 3.478

8.  A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas.

Authors:  Arman Jahangiri; Jeffrey R Wagner; Melike Pekmezci; Anne Hiniker; Edward F Chang; Sandeep Kunwar; Lewis Blevins; Manish K Aghi
Journal:  Neurosurgery       Date:  2013-07       Impact factor: 4.654

9.  Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma.

Authors:  William C McDonald; Nilanjana Banerji; Kelsey N McDonald; Bridget Ho; Virgilia Macias; Andre Kajdacsy-Balla
Journal:  Arch Pathol Lab Med       Date:  2016-05-26       Impact factor: 5.534

10.  Cell type-specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas.

Authors:  S L Asa; L A Puy; A M Lew; V C Sundmark; H P Elsholtz
Journal:  J Clin Endocrinol Metab       Date:  1993-11       Impact factor: 5.958

View more
  4 in total

Review 1.  Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options.

Authors:  P D Delgado-López; J Pi-Barrio; M T Dueñas-Polo; M Pascual-Llorente; M C Gordón-Bolaños
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

Review 2.  Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).

Authors:  Nèle Lenders; Ann McCormack
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 3.  Management of non-functioning pituitary adenomas: surgery.

Authors:  David L Penn; William T Burke; Edward R Laws
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 4.  A challenging TSH/GH co-secreting pituitary adenoma with concomitant thyroid cancer; a case report and literature review.

Authors:  Jee Hee Yoon; Wonsuk Choi; Ji Yong Park; A Ram Hong; Sung Sun Kim; Hee Kyung Kim; Ho-Cheol Kang
Journal:  BMC Endocr Disord       Date:  2021-08-30       Impact factor: 2.763

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.